Physician profile
Kyle G Smith
NPI 1184663726
$3,460.89
in general payments reported to CMS, 2019-2025
10 companies · $347 in 2025
The $347 reported for 2025 was more than what a typical Psychiatry provider received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $354 · 2020: $221 · 2021: $129 · 2022: $645 · 2023: $934 · 2024: $832 · 2025: $347.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,944 · Education: $168.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,944.41 |
| Education | $167.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $1,146.21 | 2022-2025 | Austedo Xr, Uzedy, Austedo Xr |
| Otsuka America Pharmaceutical, INC. | $1,037.24 | 2019-2025 | Rexulti, Nuedexta, Abilify Maintena |
| Neurocrine Biosciences, INC. | $759.55 | 2019-2025 | Ingrezza |
| Lundbeck LLC | $164.31 | 2022-2025 | Rexulti |
| Sunovion Pharmaceuticals INC. | $116.84 | 2019 | |
| Vanda Pharmaceuticals INC. | $109.43 | 2019-2022 | |
| Axsome Therapeutics, INC. | $44.16 | 2023 | Auvelity |
| Janssen Pharmaceuticals, INC | $37.27 | 2020-2023 | Invega Sustenna |
| Avanir Pharmaceuticals, INC. | $25.79 | 2020 | |
| E.R. Squibb & Sons, L.L.C. | $20.09 | 2025 | Cobenfy |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kyle Smith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.